Compensatory responses have been previously reported in the context of AD, where an increase in serum/plasma levels of glutamine (a neuroprotectant) and BDNF (a key regulator of neuronal growth and survival) appear early, followed by a decline in the advanced stages of the condition [61, 62]. The gene discussed is BDNF; the disease is Alzheimer disease.